| [1] |
Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249.
|
| [2] |
Fan L，Strasser-Weippl K，Li JJ，et al. Breast cancer in China[J]. Lancet Oncol，2014，15(7)：e279-e289.
|
| [3] |
Shamoo Y. Structural insights into BRCA2 function[J]. Curr Opin Struct Biol，2003，13(2)：206-211.
|
| [4] |
Hall J，Lee M，Newman B，et al. Linkage of early-onset familial breast cancer to chromosome 17q21[J]. Science，1990，250(4988)：1684-1689.
|
| [5] |
Wooster R，Neuhausen S，Mangion J，et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13[J]. Science，1994，265(5181)：2088-2090.
|
| [6] |
Wooster R，Bignell G，Lancaster J，et al. Identification of the breast cancer susceptibility gene BRCA2[J]. Nature，1995，378(6559)：789-792.
|
| [7] |
Roy R，Chun J，Powell SN.BRCA1 and BRCA2: different roles in a common pathway of genome protection[J]. Nat Rev Cancer，2012，12(1)：68-78.
|
| [8] |
Stewart M，Duncan ED，Coronado E，et al. Tuning BRCA1 and BARD1 activity to investigate RING ubiquitin ligase mechanisms: Tuning BRCA1 ubiquitin ligase activity[J]. Protein Sci，2017，26(3)：475-483.
|
| [9] |
Tarsounas M，Sung P. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication[J]. Nat Rev Mol Cell Biol，2020，21(5)：284-299.
|
| [10] |
Clark SL，Rodriguez AM，Snyder RR，et al. Structure-function of the tumor suppressor BRCA1[J]. Comput Struct Biotechnol J，2012，1(1)：e201204005.
|
| [11] |
Deng CX，Brodie SG. Roles of BRCA1 and its interacting proteins[J]. Bioessays，2000，22(8)：728-737.
|
| [12] |
Leung CC，Glover JN. BRCT domains: easy as one, two, three[J]. Cell Cycle，2011，10(15)：2461-2470.
|
| [13] |
Fernandes VC，Golubeva VA，Di Pietro G，et al. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation[J]. J Biol Chem，2019，294(15)：5980-5992.
|
| [14] |
Pellegrini L，Yu DS, Lo T，et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex[J]. Nature，2002，420(6913)：287-293.
|
| [15] |
Davies AA，Masson JY，McIlwraith MJ，et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein[J]. Mol Cell，2001，7(2)：273-282.
|
| [16] |
Yang H. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure[J]. Science，2002，297(5588)：1837-1848.
|
| [17] |
Patel KJ，Yu VP，Lee H，et al. Involvement of BRCA2 in DNA repair[J]. Mol Cell，1998，1(3)：347-357.
|
| [18] |
Cox MM，Goodman MF，Kreuzer KN，et al. The importance of repairing stalled replication forks[J]. Nature，2000，404(6773)：37-41.
|
| [19] |
Moynahan ME，Pierce AJ，Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks[J]. Mol Cell，2001，7(2)：263-272.
|
| [20] |
Tutt A，Bertwistle D，Valentine J，et al. Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences[J]. EMBO J，2001，20(17)：4704-4716.
|
| [21] |
Xia F，Taghian DG，DeFrank JS，et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining[J]. Proc Natl Acad Sci USA，2001，98(15)：8644-8649.
|
| [22] |
Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2[J]. Science，2014，343(6178)：1470-1475.
|
| [23] |
Isono M，Niimi A，Oike T，et al. BRCA1 directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation[J]. Cell Rep，2017，18(2)：520-532.
|
| [24] |
Mirman Z，Lottersberger F，Takai H，et al. 53BP1-RIF1-shieldin counteracts DSB resection through CST-and polα-dependent fill-in[J]. Nature，2018，560(7716)：112-116.
|
| [25] |
Zimmermann M，Lottersberger F，Buonomo SB，et al. 53BP1 regulates DSB repair using Rif1 to control 5’ end resection[J]. Science，2013，339(6120)：700-704.
|
| [26] |
Bunting SF，Callén E，Wong N，et al. 53BP1 inhibits homologous recombination in BRCA1-deficient cells by blocking resection of DNA breaks[J]. Cell，2010，141(2)：243-254.
|
| [27] |
Godet I，Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer[J]. Integr Cancer Sci Ther，2017，4(1)：10.
|
| [28] |
Ludwig KK，Neuner J，Butler A，et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review[J]. Am J Surg，2016，212(4)：660-669.
|
| [29] |
Domchek S，Kaunitz AM. Use of systemic hormone therapy in BRCA mutation carriers[J]: Menopause，2016，23(9)：1026-1027.
|
| [30] |
Zhong Q，Peng HL，Zhao X，et al. Effects of BRCA1-and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis[J]. Clin Cancer Res，2015，21(1)：211-220.
|
| [31] |
Baretta Z，Mocellin S，Goldin E，et al. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis[J]. Medicine，2016，95(40)：e4975.
|
| [32] |
Copson ER，Maishman TC，Tapper WJ，et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study[J]．Lancet Oncol，2018，19(2)：169-180.
|
| [33] |
Ghelli Luserna di Rora’A，Iacobucci I，Martinelli G. The cell cycle checkpoint inhibitors in the treatment of leukemias[J]. J Hematol Oncol，2017，10(1)：77.
|
| [34] |
Zhu J，Jia W，Wu C，et al. Base excision repair gene polymorphisms and wilms tumor susceptibility[J]. EBioMedicine，2018，33：88-93.
|
| [35] |
Germano G，Amirouchene-Angelozzi N，Rospo G，et al. The clinical lmpact of the genomic landscape of mismatch repair-deficient cancers[J]. Cancer Discov，2018，8(12)：1518-1528.
|
| [36] |
Kaniecki K，De Tullio L，Greene EC. A change of view: homologous recombination at single-molecule resolution[J]. Nat Rev Genet，2018，19(4)：191-207.
|
| [37] |
Balmus G，Pilger D，Coates J，et al. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks[J]. Nat Commun，2019，10(1)：87.
|
| [38] |
Aparicio T，Baer R，Gautier J. DNA double-strand break repair pathway choice and cancer[J]. DNA Repair，2014，19：169-175.
|
| [39] |
Mengwasser KE，Adeyemi RO，Leng Y，et al. Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets[J]. Mol Cell，2019，73(5)：885-899.
|
| [40] |
Fong PC，Yap TA，Boss DS，et al. Poly(ADP)-Ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free Interval[J]. J Clin Oncol，2010，28(15)：2512-2519.
|
| [41] |
Robson M，Ruddy KJ，Im SA，et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial[J]. Eur J Cancer，2019，120：20-30.
|
| [42] |
Litton JK，Rugo HS，Ettl J，et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med，2018，379(8)：753-763.
|
| [43] |
U．S.Food&Drug Administration.FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer[EB/OL]．(2018-12-14)[2020-06-15]．
URL
|
| [44] |
Litton JK，Scoggins ME，Hess KR，et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant[J]. J Clin Oncol，2020，38(5)：388-394.
|
| [45] |
Han HS，Diéras V，Robson M，et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study[J]. Ann Oncol，2018，29(1)：154-161.
|
| [46] |
Diéras VC，Han HS，Kaufman B，et al. Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer[J]. Ann Oncol，2019，30：v857-v858.
|
| [47] |
Loibl S，O’Shaughnessy J，Untch M，et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial[J]. Lancet Oncol，2018，19(4)：497-509.
|